Better effect of vaccine in MS patients with more B cells


MS patients treated with rituximab have a better effect of covid-19 vaccine if the level of B cells is higher. This is shown by a new study from Uppsala University which is published in the journal JAMA Network Open. In patients with B cells of 40 / µL (microliters) or more, 9 out of 10 patients developed a protective level of antibodies, while there were significantly fewer among those with lower levels.

Read the press release on Mynewsdesk (in Swedish).
Read more about the study (in Swedish).

Last modified: 2023-02-01